TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
SSY Group ( (HK:2005) ) just unveiled an announcement.
SSY Group Limited has announced the approval for drug production and registration of two new chemical drug products by the National Medical Products Administration of China. The newly approved products, Calcium Gluconate and Sodium Chloride Injection and Morinidazole and Sodium Chloride Injection, are expected to enhance the company’s product portfolio, addressing conditions such as acute hypocalcemia and gynecological pelvic inflammatory diseases. This development signifies a strategic advancement in SSY Group’s market positioning, potentially strengthening its competitive edge in the pharmaceutical industry.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited is a company operating in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company is known for its range of calcium preparation products and other pharmaceutical solutions aimed at treating various medical conditions.
YTD Price Performance: -7.62%
Average Trading Volume: 14,295,131
Technical Sentiment Signal: Hold
Current Market Cap: HK$9.27B
For an in-depth examination of 2005 stock, go to TipRanks’ Overview page.